HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pelosi aide expects health care reform by Easter

This article was originally published in The Tan Sheet

Executive Summary

Congress "can pass a reconciliation bill and have a health reform bill by Easter recess," says Wendell Primus, a top aide for Speaker of the House Nancy Pelosi, D-Calif. Primus, a senior Pelosi advisor on budget and health issues who spoke at Academy Health's National Health Policy Conference in Washington Feb. 9, said the only way to pass a bill is for the House to use the budget reconciliation process to change a provision in the Senate version with which the House Democratic majority disagrees (1"The Tan Sheet" Jan. 18, 2010). Republican congressional aides at the conference said they could support passing a series of smaller health-focused reform bills, such as Medicare reforms or other targeted refinements. But a Democratic aide from the Senate Finance Committee suggested Democrats are unlikely to support that approach

You may also be interested in...



CHPA Reminds Congress OTC Benefits Belong In Health Care Reform

The Consumer Healthcare Products Association pushes for broader OTC drug benefits in health care reform legislation while urging the House to adopt language from the Senate bill that allows at least for limited coverage of OTCs in health savings and flexible spending accounts

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS134674

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel